HLX51 / Fosun Pharma, Shanghai Henlius Biotech - LARVOL DELTA

Henlius 2023 H1 Results: Achieved record profits and RMB2.5 billion revenues, opening a new chapter of high-quality growth (PRNewswire) - "During the reporting period, the phase 1 clinical trial for the company's self-developed HLX51, a novel humanized agonistic anti-OX40 mAb for the treatment of patients with advanced/metastatic solid tumours and lymphomas has been approved by the NMPA."

Trial status • Hematological Malignancies • Lymphoma • Oncology • Solid Tumor

Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of HLX51 in Patients With Solid Tumor or Lymphoma (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: Shanghai Henlius Biotech | Trial completion date: Oct 2024 ➔ Oct 2026 | Initiation date: Jun 2023 ➔ Jun 2024 | Trial primary completion date: May 2024 ➔ May 2025

Metastases • Trial completion date • Trial initiation date • Trial primary completion date • Gastrointestinal Cancer • Hematological Malignancies • Hepatocellular Cancer • Lymphoma • Oncology • Solid Tumor

Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of HLX51 in Patients With Solid Tumor or Lymphoma (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: Shanghai Henlius Biotech

Metastases • New P1 trial • Gastrointestinal Cancer • Hematological Malignancies • Hepatocellular Cancer • Lymphoma • Oncology • Solid Tumor